Biological E seeks DCGI's nod for phase-3 trial of Corbevax as booster dose for Covishield, Covaxin

Biological E has sought permission from DCGI to conduct the phase-3 clinical trial for its Covid-19 vaccine Corbevax as a single booster dose for those who have been fully vaccinated with Covishield or Covaxin.

Hyderabad-based pharmaceutical company Biological E has sought permission from India's drug regulator to conduct the phase-3 clinical trial for its Covid-19 vaccine Corbevax as a single booster dose for those who have been fully vaccinated with Covishield or Covaxin.

Currently, phase 2/3 clinical trials of the second indigenously developed Corbevax, an RBD protein sub-unit vaccine to be administered in adults aged 18 years to 80 years, is underway and the results are likely to be declared this month.